BCM
XLO icon

Bridgeway Capital Management’s Xilio Therapeutics XLO Stock Holding History

Bridgeway Capital Management’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,006
Closed -$35.9K – 1319
2025
Q4 		$35.9K Hold
4,006
– – ﹤0.01% 1193
2025
Q3 		$47.3K Hold
4,006
– – ﹤0.01% 1171
2025
Q2 		$38.1K Sell
4,006
-1,071
-21% -$11.3K ﹤0.01% 1146
2025
Q1 		$51.5K Hold
5,077
– – ﹤0.01% 1119
2024
Q4 		$67.9K Hold
5,077
– – ﹤0.01% 1142
2024
Q3 		$56K Hold
5,077
– – ﹤0.01% 1205
2024
Q2 		$67.3K Hold
5,077
– – ﹤0.01% 1196
2024
Q1 		$76.8K Sell
5,077
-6,029
-54% -$58.2K ﹤0.01% 1237
2023
Q4 		$85.5K Buy
11,106
+3,214
+41% +$63.6K ﹤0.01% 1261
2023
Q3 		$233K Hold
7,892
– – 0.01% 1068
2023
Q2 		$289K Hold
7,892
– – 0.01% 1055
2023
Q1 		$351K Hold
7,892
– – 0.01% 966
2022
Q4 		$297K Buy
7,892
+2,458
+45% +$82.9K 0.01% 992
2022
Q3 		$221K Buy
+5,434
New +$211K 0.01% 1122

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bridgeway Capital Management's XLO Position: Q1 2026 in Review

Bridgeway Capital Management sold out of Xilio Therapeutics (XLO) in Q1 2026, closing a stake of 4,006 shares — an estimated $35.9K sold.

Bridgeway Capital Management first reported a position in XLO in Q3 2022 and held it in 14 quarters. The position peaked at $351K in Q1 2023. 24 funds tracked by Wall St. Rank hold XLO as of Q1 2026.

  • Bridgeway Capital Management reported no remaining Xilio Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bridgeway Capital Management sold 4,006 Xilio Therapeutics shares in Q1 2026, an estimated $35.9K.
  • Bridgeway Capital Management first reported a position in Xilio Therapeutics in Q3 2022 and held it in 14 quarters.
  • Bridgeway Capital Management's Xilio Therapeutics position peaked at $351K in Q1 2023.
  • 24 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.